UK-432,097

In today's world, UK-432,097 has captured the attention and interest of a large number of people. Whether due to its impact on society, its relevance in history, its influence on popular culture or its importance in the professional field, UK-432,097 has become a topic of great interest to a wide audience. Learning more about UK-432,097 is not only a way to expand our knowledge, but also to better understand the world around us. In this article we will explore various aspects related to UK-432,097, analyzing its origin, its evolution over time, its impact in different areas and the future perspectives that this topic presents to us.

UK-432,097
Kekulé skeletal formula of UK-432,097
Kekulé skeletal formula of UK-432,097
Names
Systematic IUPAC name
(12R,13R,14S,15S)-26--N-ethyl-13,14-dihydroxy-3,8-dioxo-4,7,9-triaza-2(9,2)-purina-11(2)-pyridina-10(4,1)-piperidina-1(2)-oxolanaundecaphane-15-carboxamide
Identifiers
3D model (JSmol)
Abbreviations UK-432,097
ChEMBL
ChemSpider
UNII
  • InChI=1S/C40H47N11O6/c1-2-41-37(54)33-31(52)32(53)39(57-33)51-24-46-30-34(45-23-28(25-11-5-3-6-12-25)26-13-7-4-8-14-26)48-35(49-36(30)51)38(55)43-19-20-44-40(56)47-27-16-21-50(22-17-27)29-15-9-10-18-42-29/h3-15,18,24,27-28,31-33,39,52-53H,2,16-17,19-23H2,1H3,(H,41,54)(H,43,55)(H2,44,47,56)(H,45,48,49)/t31-,32+,33-,39+/m0/s1 ☒N
    Key: ZOTHAEBAWXWVID-HXEFRTELSA-N ☒N
  • O=C(NCC)((O)1O)O1N2C=NC3=C(NCC(C4=CC=CC=C4)C5=CC=CC=C5)N=C(C(NCCNC(NC6CCN(C7=NC=CC=C7)CC6)=O)=O)N=C32
  • O=C(NC2CCN(c1ncccc1)CC2)NCCNC(=O)c5nc3c(ncn34O(C(=O)NCC)(O)4O)c(n5)NCC(c6ccccc6)c7ccccc7
Properties
C40H47N11O6
Molar mass 777.887 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).
☒N verify (what is checkY☒N ?)

UK-432,097 is a drug developed by Pfizer for the treatment of chronic obstructive pulmonary disease, which acts as a potent and selective agonist of the adenosine A2A receptor.[1] It was discontinued from clinical trials following poor efficacy results,[2] but its high selectivity has made it useful for detailed mapping of the internal structure of the A2A receptor.[3]

References

  1. ^ Russo, Cristina; Arcidiacono, Giuseppe; Polosa, Riccardo (2006). "Adenosine receptors: promising targets for the development of novel therapeutics and diagnostics for asthma". Fundamental and Clinical Pharmacology. 20 (1): 9–19. doi:10.1111/j.1472-8206.2005.00388.x. PMID 16448391. S2CID 20463970.
  2. ^ Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease. ClinicalTrials.gov
  3. ^ Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG, Cherezov V, Stevens RC (March 2011). "Structure of an Agonist-Bound Human A2A Adenosine Receptor". Science. 332 (6027): 322–7. Bibcode:2011Sci...332..322X. doi:10.1126/science.1202793. PMC 3086811. PMID 21393508.


Stub icon

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about an organic compound is a stub. You can help Wikipedia by expanding it.